Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain Ravaud

Showing results (191-200 of 221) with videos related to

Pageof 23
Sort By:
BJU International|April 2, 2020
Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinomaSumanta K Pal, David F McDermott, Michael B Atkins, et al.
Nature Medicine|May 4, 2021
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancerThomas Powles, Danielle Carroll, Simon Chowdhury, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2016
Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell CarcinomaThomas Powles, Mark R Lackner, Stéphane Oudard, et al.
Cancer Research|January 15, 2017
Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell CarcinomasMaeva Dufies, Sandy Giuliano, Damien Ambrosetti, et al.
The New England Journal of Medicine|October 11, 2016
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after NephrectomyAlain Ravaud, Robert J Motzer, Hardev S Pandha, et al.
Theranostics|May 4, 2018
Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinomaMaeva Dufies, Marie Nollet, Damien Ambrosetti, et al.
European Urology|June 30, 2021
Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al.
European Urology|November 9, 2019
Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancerAlfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al.
European Urology|March 8, 2021
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical TrialThomas Powles, Michael B Atkins, Bernard Escudier, et al.
Lancet (London, England)|December 23, 2017
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialThomas Powles, Ignacio Durán, Michiel S van der Heijden, et al.
Pageof 23

Showing results (191-200 of 221) with videos related to

Sort By:
Pageof 23
BJU International|April 2, 2020
Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinomaSumanta K Pal, David F McDermott, Michael B Atkins, et al.
Nature Medicine|May 4, 2021
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancerThomas Powles, Danielle Carroll, Simon Chowdhury, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2016
Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell CarcinomaThomas Powles, Mark R Lackner, Stéphane Oudard, et al.
Cancer Research|January 15, 2017
Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell CarcinomasMaeva Dufies, Sandy Giuliano, Damien Ambrosetti, et al.
The New England Journal of Medicine|October 11, 2016
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after NephrectomyAlain Ravaud, Robert J Motzer, Hardev S Pandha, et al.
Theranostics|May 4, 2018
Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinomaMaeva Dufies, Marie Nollet, Damien Ambrosetti, et al.
European Urology|June 30, 2021
Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al.
European Urology|November 9, 2019
Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancerAlfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al.
European Urology|March 8, 2021
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical TrialThomas Powles, Michael B Atkins, Bernard Escudier, et al.
Lancet (London, England)|December 23, 2017
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialThomas Powles, Ignacio Durán, Michiel S van der Heijden, et al.
Pageof 23